Fenofibrate for Lipid Disorders
Abbott Laboratories has received approval to market a new formulation of fenofibrate tablets (Drug TriCor) to treat elevated cholesterol, triglyceride, and apolipoprotein B levels. The new formulation can be taken with or without food.
Until now, this drug had to be taken with food to enable its absorption. The new 145-mg and 48-mg tablets offer the same effectiveness than the previous 160-mg and 54-mg tablets. Nanoparticle technology allows the drug to dissolve faster and more completely in the gastrointestinal tract. The product remains a once-daily treatment.
Patients should not take fenofibrate with statin drugs because of the potential for serious side effects that may lead to acute renal failure. The drug is not indicated for patients with serious liver, kidney or gallbladder disease or those who may be allergic or sensitive to it.
Because the tablets may affect liver chemistry results, regular periodic liver tests should be performed during therapy. Stomach pain during therapy can be a sign of gallstones or inflammation of the pancreas.
Fenofibrate generic may also cause muscle disease, allergic reactions, and changes in blood chemistry. If patients experience unexpected muscle pain, weakness, or tenderness while taking fenofibrate, they should contact their health care provider immediately.
Abbott markets the drug in the U.S. through an agreement with Fournier of France.
